INTRODUCTION
Breast cancer is the most common cancer affecting females worldwide and accounts for roughly 25% of all cancers in women. Survival rates for women with breast cancer are improving; but are still poorest for patients who present with late stage disease, patient cannot be offered radical cure and it also increases the cost of treatment and causes both physical and psychological trauma to the patient. Consequently, there is great interest in providing improved care to patients with advanced breast cancer. Locally Advanced Breast Cancer is a heterogenous clinical entity that includes patients with large tumour >5cm primary breast tumors or T4 tumours with chest wall involvement, peau d' orange appearance or ulceration of the skin,or inflammatory cancer and /or extensive clinical lymph node involvement as defined by the N2 and N3 categories from the American Joint Committee on Cancer TNM classification system. 1 Locally Advanced Breast Cancer comprises a diverse array of clinic-pathologic features. Down-staging by neoadjuvant chemotherapy allows breast surgery to be undertaken in some patients considered inoperable prior to treatment and even permits breast conservative surgery. 2 The Pathological Complete Response (PCR) is considered as biological marker for survival outcomes.
The PCR is considered when there is complete eradication of locoregional disease. 3, 4 Knowledge of a patient's response to neoadjuvant therapy is essential and has important consequences for optimal and costeffective management. Accurate response assessment also aids eventual surgical planning, facilitating the correct surgical procedure to be undertaken, whether this is breast conserving surgery or mastectomy.
The objective of this study was to assess the response to Neo Adjuvant Chemotherapy in LABC in terms of pathological response, overall survival, feasibility of breast conservative surgery and convert inoperable cases to resectability. (Figure 1 ).
METHODS

Figure 1: Response to neo adjuvant chemotherapy.
Surgery was performed in all these patients after Neoadjuvant chemotherapy; 25 (83.33%) patients underwent Modified Radical Mastectomy (MRM),5 (16.66 %) had Breast Conservation Surgery (BCS); all had Axillary lymph node dissection and followed by adjuvant chemotherapy.All patients undergoing breast conservation surgery were given adjuvant radiotherapy.All the patients with receptor positive cancer were given hormone therapy (Figure 2 ). \ The mean follow-up period was 15 months (range: 3-26 months) in the patients undergoing Breast Conservative Surgery and 16.1 months (range: 4-51 months) for the patients having modified radical mastectomy respectively. No patient in either groups had local or distant metastasis.
The most common toxicity criteria following neoadjuvant chemotherapy we encountered was grade 2 alopecia (25 patients ;83.33%), followed by fatigue (20 patients; 66.66%) Arthralgia and myalgia were developed in 5 patients (16.66%) whereas febrile neutropenia occurred in only 3 patients (10 %). All patients completed the treatment protocol without interruption of treatment.
DISCUSSION
Locally advanced breast carcinoma encompasses a heterogenous collection of breast neoplasia with widely different clinical and biological characterstics. 6 Neoadjuvant chemotherapy for locally advanced advanced breast carcinoma patients has significantly changed management options over the last 4 decades. It provides appropriate local control, the possibility of breast conserving surgery and increased survival rate in LABC.
The overall response to neoadjuvant chemotherapy in this study was 76.66 %, partial= 3 (3%) and complete response = 20 (66.66%). Several other studies have shown a similar overall objective response of the primary tumor in patients with locally advanced breast cancer ranging from 71 to 87 %. 7, 8, 9 On the other hand, the present results are much higher than that reported by Yadav et al who found that only 23 % showed response to neoadjuvant chemotherapy. 10 Another study by Tamer et al. in 2010 also showed much lesser overall response rates to neoadjuvant chemotherapy 54.5 %(CR 3% and PR 51.5%) and Kim et al also reported that the overall response rate to neoadjuvant chemotherapy is 60 %(CR 4 % and PR 56%) respectively. 11, 12 Several studies have documented the feasibility and safety of breast conservation for locally advanced breast cancer after pre-operative chemotherapy. Breast conservation is possible in 27-90% of patients after preoperative chemotherapy. 13, 14 In this study,5 patients (16.66 %) underwent Breast conservative surgery after neoadjuvant chemotherapy. Similar results were reported by other authors. Danforth et al conducted their study on 126 patients with locally advanced breast cancer who received neoadjuvant chemotherapy. They found that 42 (33%) of them were downstaged to the extent that breast conservation surgery became a feasible technique for them. 15 In other study, Yadav et al reported that 23% of patients with locally advanced breast cancer are good candidates for breast conservation surgery after neoadjuvant chemotherapy provided that they are carefully selected. 
